
First at-home test to screen for cervical cancer approved by FDA
May 9 (UPI) -- The U.S. Food and Drug Administration on Friday approved Teal Health to provide the nation's first at-home test kit to screen for cervical cancer.
The Teal Wand, which will be available for those age 25 to 65 at average risk, tests for human papillomavirus, or HPV, a virus that causes most cervical cancers.
Teal Health CEO Kara Egan didn't say how much the test would cost. Egan anticipates the test will be covered by insurance.
They will first be available in California in June and then expand nationwide.
Until now, the only way to screen for cervical cancer was in a doctor's office during a pelvic exam.
"As a mom and a woman, I get how easy it is to put your own health last," Egan said in a news release. "That's why this FDA approval means so much; it's not just about an innovative new product, it's about finally giving women an option that actually makes sense for their lives -- something that can be done quickly and comfortably at home. Because when we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day."
Because of the invasive aspect, the company found 1 in 4 women in the United States are behind in testing.
Dr. Emeline Aviki, a gynecologic-oncologist at New York University Langone Health, who worked on initial studies, told CNBC: "It's not a fun exam and it's the easiest thing to cancel."
She worked on early studies to validate the new test.
In a Teal Health study, 86% of participants thought they would more likely stay up-to-date with cervical cancer screening if they could do it at home. And 94% said they would prefer to self-collect at home if it were accurate.
In the new vaginal swab, a speculum is used and samples of cells are collected from the cervix.
Last year, the FDA approved a similar swab, also performed by patients themselves, that's collected in a doctor's office.
"What's different about this new indication is that this sample can be collected at home and not in a medical setting," Dr. George Sawaya, a gynecologist at University of California San Francisco Health, told CNBC. You have to logically believe that would increase access if people's main barrier was getting to a medical setting."
Patients can order the test kit after a telehealth appointment with a doctor. The swab is then mailed to a lab for analysis.
The product initially must be prescribed by one of Teal Health's virtual providers.
If there is a positive test, women may need additional tests in a doctor's office.
The American Cancer Society estimates that 13,360 women will be diagnosed with cervical cancer this year and about 4,320 women will die. "Cervical cancer incidence rates decreased by more than half from the mid-1970s to the mid-2000s because of widespread screening uptake," ACA said.
Cervical cancer mortality rates also dropped by more than half since the mid-1970s.
The study found the test detects cervical precancer 96% of the time.
"As a Principal Investigator in the SELF-CERV trial, I saw firsthand how receptive and excited women were to use the Teal Wand," Dr. Christine Conageski, associate professor, OB-GYN and director of the Complex Dysplasia Clinic at the University of Colorado, said in the company's news release. "Cervical cancer is largely preventable, yet screening rates in the U.S. continue to lag, and the FDA approval of this at-home Teal Wand self-collection device is a critical step forward. It offers an evidence-based way to expand access without compromising accuracy."
She noted women must do more than be tested.
"But access is only part of the solution," she said. "Comprehensive screening must go hand in hand with structured, reliable follow-up."
Last year, researchers found a new urine test might help doctors more easily screen for cervical cancer. The test looks for proteins generated by a type of cancer-causing human papillomavirus, HPV 16.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Urgent dried fruit recall in 19 states over serious health risk
Dried fruit sold in multiple states has been recalled due to a serious health risk. Turkana Food Inc issued a recall on 352 cases of its Floria Dried Apricots, according to a press release shared by the U.S. Food and Drug Administration on Thursday. The product was recalled because it contains an undeclared allergen, sulfites, or 'chemicals used as preservatives' added to foods, beverages, and medications to prevent them from spoiling, according to the Cleveland Clinic. According to the FDA, the recall came after routine sampling, performed by the New York State Department of Agriculture, revealed that the product contained sulfites, which 'were not listed on the product labeling.' As Turkana Food Inc continues an 'investigation to correct the issue with the manufacturer,' production and distribution of the product by the FDA has been ceased. The recalled Floria Dried Apricots were sold at stores in 19 states: Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, and Virginia. The product has the LOT number 440090478-15-333 on the bottom portion of the packaging. The UPC Label 2539560010 is marked by a sticker on the side of the packaging. The expiration date of November 2026 is also on the bottom of the packaging. Consumers who have the recalled product should not consume it. The FDA is also urging consumer to return the dried apricots to the place of purchase for a full refund. There have been no reported illnesses so far. Most often, people with asthma have allergies and sensitivities to sulfites. Earlier this week, P. East Trading Corp. also urgently recalled its Salted Smoked Split Herring because it may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death. Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation. Then, on Tuesday, 6,668 cases of Breyers Chocolate Truffle Ice Cream was also recalled following customer concerns that there was a mislabeling error. The recall came after it was found that the tubs actually contained Rocky Road ice cream. The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.
Yahoo
2 hours ago
- Yahoo
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
Check Your Freezer—Popular Ice Cream Recalled Due To Potentially Life-Threatening Allergen
Summer is just around the corner and ice cream is the quintessential warm weather treat. But if you have a carton or two chilling in your freezer, you might want to check the label. Breyers recently issued a recall on 6,668 cases of ice cream due to "undeclared allergens and mislabeled product." According to the FDA, the voluntary recall was initiated on June 2 because Breyers Rocky Road, which contains the almonds, was packaged incorrectly. The ice cream was packaged in Breyers Chocolate Truffle tubs with Rocky Road lids, which may be a concern for anyone who purchased the product and has a nut allergy. While almonds are a tree nut, the Chocolate Truffle tubs offer misleading ingredient information. The tubs say "may contain tree nuts" while the lids say "contain almonds." The FDA classified the recall as a Class II, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." So how do you know if your ice cream is affected? Take a peek at the packaging of your Breyers ice cream tub. Affected products have the lot number: JUL1026GB3 and UPC code: 077567457288. In a statement to PEOPLE, Breyers says: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails